Hydrocortisone hemisuccinate (Compound)

Synonyms:hydrocortisone hemisuccinate, Hydrocortisone succinate, 2203-97-6, Cortisol succinate, Hydrocortisone 21-hemisuccinate, Cortisol hemisuccinate, Cortisol 21-hemisuccinate, Solu-Cortef, Hydrocortisone hydrogen succinate, CHEBI:31677, UNII-IHV1VP592V, IHV1VP592V, MLS000028530, NSC-7576, Buccalsone, Flebocortid, Solucortef, Arcocort, Hycorace, Intracort, Nordicort, Oralsone, Corlan, Emi-Corlin, Solu-Hizon, Solu-Glyc, SMR000058328, 11beta,17alpha,21-trihydroxypregn-4-ene-3,20-dione 21-succinate, EF-Cortelan soluble, 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid, Aacicortisol, Aftasome, Oralsome, Saxizon, 11beta,17,21-Trihydroxypregn-4-ene-3,20-dione 21-(hydrogensuccinate), NSC9152, Hydrocortisone Roussel, Hydrocortisone Leurquin, Hydrocortisone hemisuccinate sodium salt, NCGC00022248-03, 125-04-2, Cortisol, hydrogen succinate, Hydrocortisone 21-(hydrogen succinate), Hydrocortisone 21-succinate, Hydrocortisonum Hemisuccinatum, Cortisol, 21-(hydrogen succinate), hydrocortisone 21-hemisuccinate*free acid, EINECS 218-612-3, Hydrocortisone 21-he, ST075193, Hydroxycortisone succinate, 83784-20-7, Opera_ID_1732, hydrocortisone-hemisuccinate, CHEMBL977, Succinic acid hydrocortisone, SCHEMBL7664, Lopac0_000623, MLS001146928, MLS002207249, Hydrokortison-21-Hemisuccinat, Hydrocortisone succinate [JAN], 4-((11,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl)oxy)-4-oxobutanoic acid, Hydrocortisone succinate (JP17), DTXSID40872905, Cortisol 21-(hydrogen succinate), HMS2235G13, HMS3259A14, 4-(2-((8S,9S,10R,11S,13S,14S,17R)-11,17-Dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethoxy)-4-oxobutanoic acid, ZINC4097472, BDBM50016931, LMST02030126, s5972, AKOS015969742, AC-6828, DB14545, GS-6198, NC00567, (11-beta)-21-(3-Carboxy-1-oxopropoxy)-11,17-dihydroxypreg-4-ene-3,20-dione, Preg-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11-beta)-, 3-{[2-((1S,10S,11S,15S,17S,2R,14R)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyc lo[8.7.0.0<2,7>.0<11,15>]heptadec-6-en-14-yl)-2-oxoethyl]oxycarbonyl}propanoic acid, 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethoxy]-4-oxo-butanoic acid, CS-0013125, EN300-55845, D01442, A815861, Hydrocortisone 21-hemisuccinate, analytical standard, W-107508, Q27104202, Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11, 17-dihydroxy-, Hydrocortisone hydrogen succinate, British Pharmacopoeia (BP) Reference Standard, Hydrocortisone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard, Pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, (11b)-, 4-[2-[(8S,9S,10R,11S,13S,14S,17R)-10,13-dimethyl-11,17-bis(oxidanyl)-3-oxidanylidene-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethoxy]-4-oxidanylidene-butanoic acid, 4-{2-[(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl]-2-oxoethoxy}-4-oxobutanoic acid
Pubchem:PUBCHEM:16623
Id:a2015ead-82c8-5f56-a162-06a66280c434
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Hydrocortisone hemisuccinate's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Hydrocortisone hemisuccinate.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Hydrocortisone hemisuccinate.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.